# US 2024/0002836 A1 · Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002836 A1
- Document ID: US20240002836A1
- Status: Published application
- Kind: A1
- Application number: 18/156,138
- Filed: 2023-01-18
- Published: 2024-01-04
- Earliest claimed: 2008-04-11
- Assignees: Chugai Seiyaku Kabushiki Kaisha
- Applicants: Chugai Seiyaku Kabushiki Kaisha
- Inventors: Tomoyuki IGAWA; Shinya ISHII; Atsuhiko MAEDA; Takashi NAKAI
- Web page: https://patentgrep.com/patent/US20240002836A1

## CPC

- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/244: {Interleukins [IL]}
- C07K 16/248: {IL-6}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- G01N 33/6854: {Immunoglobulins}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/544: {to the airways}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/552: {Veterinary vaccine}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 2760/16111: Influenzavirus A, i.e. influenza A virus
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20071: Demonstrated in vivo effect
- G01N 2500/00: Screening for compounds of potential therapeutic value
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.

## Claims

### Claim 1

An antigen-binding molecule having a KD(pH5.8)/KD(pH7.4) value, defined as the ratio of KD for the antigen at pH 5.8 and KD for the antigen at pH 7.4, of 2 or higher.

### Claim at position 2

2-8. (canceled)

### Claim 9

A method for improving the pharmacokinetics of an antigen-binding molecule, for increasing the number of times of antigen-binding for an antigen-binding molecule, for increasing the number of antigens that can be bound by an antigen-binding molecule, for dissociating within a cell an antigen from an extracellularly-bound antigen-binding molecule, for releasing an antigen-binding molecule, which has been bound to an antigen and internalized into a cell, in an antigen-free form to the outside of the cell, or for increasing the ability of an antigen-binding molecule to eliminate an antigen in plasma by impairing the antigen-binding activity of the antigen-binding molecule at pH 5.8 as compared to that at pH 7.4.

### Claim at position 4

10-14. (canceled)

### Claim 15 (depends on 9)

The method of claim 9, wherein the KD(pH5.8)/KD(pH7.4) value, defined as the ratio of KD for the antigen at pH 5.8 and KD for the antigen at pH 7.4, is 2 or higher.

### Claim at position 6

16-17. (canceled)

### Claim 18

A method for improving the pharmacokinetics of an antigen-binding molecule, for increasing the number of times of antigen-binding for an antigen-binding molecule, for increasing the number of antigens that can be bound by an antigen-binding molecule, for dissociating within a cell an antigen from an extracellularly-bound antigen-binding molecule, for releasing an antigen-binding molecule, which has been bound to an antigen and internalized into a cell, in an antigen-free form to the outside of the cell, or for increasing the ability of an antigen-binding molecule to eliminate an antigen in plasma by substituting at least one amino acid of the antigen-binding molecule with histidine, or inserting at least one histidine into the antigen-binding molecule.

### Claim at position 8

19-23. (canceled)

### Claim 24 (depends on 18)

The method of claim 18, wherein the histidine substitution or insertion increases the KD(pH5.8)/KD(pH7.4) value, defined as the ratio of the antigen-binding activity at pH 5.8 and the antigen-binding activity at pH 7.4, as compared to the KD(pH5.8)/KD(pH7.4) value before the histidine substitution or insertion.

### Claim 25 (depends on 9)

The method of claim 9, wherein the antigen-binding molecule has an antagonistic activity.

### Claim 26 (depends on 9)

The method of claim 9, wherein the antigen-binding molecule binds to a membrane antigen or a soluble antigen.

### Claim 27 (depends on 9)

The method of claim 9, wherein the antigen-binding molecule is an antibody.

### Claim at position 13

28-50. (canceled)
